We found that the expression of genes targeted by NFE2L2 was increased in NAFL and NASH livers with mild fibrosis, but was decreased in NASH livers with more advanced fibrosis (Figure 1A). The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatohepatitis.